Drug Profile
UB 312
Alternative Names: UB-312Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator United Neuroscience
- Developer United Biomedical; United Neuroscience; Vaxxinity
- Class Antiparkinsonians; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Lewy body disease; Multiple system atrophy; Parkinson's disease
Most Recent Events
- 07 Mar 2024 Immunogenicity data from the phase I trial in Parkinson's diseases released by Vaxxinity
- 30 Jan 2024 Vaxxinity and Center for Translational Research in Neurodegenerative Disease (CTRND) enters into a R&D agreement to develop immunotherapies to prevent and mitigate Neurodegenerative diseases
- 18 Jul 2023 Interim immunogenicity data from a phase I trial in Parkinson's disease released by Vaxxinity